<DOC>
	<DOCNO>NCT00504595</DOCNO>
	<brief_summary>This study intend assess safety , efficacy , response treatment use American College Rheumatology ( ACR ) criteria 20 % improvement symptom ( ACR20 ) investigate potential biomarker profile adult patient establish rheumatoid arthritis</brief_summary>
	<brief_title>Safety Efficacy ACZ885 Adult Patients With Established Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>RA patient : Male female patient age 18 75 year ( inclusive ) . Body weight 50 100 kg ( inclusive ) . Post menopausal surgically sterile female patient allow . Female patient childbearing potential may participate already stable dose methotrexate . Additional birth control detail provide screen . Male patient must use effective contraception method study least 2 month follow completion/discontinuation study . Diagnosis RA , classify American Rheumatism Association 1987 revise criterion . Disease duration least 6 month essential . Functional status class I , II III classify accord American College Rheumatology 1991 revise criterion . Active disease evaluation ( ≥ 6 tender ≥ 6 swollen joint ) Prior treatment 13 diseasemodifying antirheumatic drug ( DMARDs ) Patients fail least 1 DMARD deem `` refractory therapy '' . It expect patient current treatment methotrexate ≤ 25 mg/week current dose stable least 3 month , however patient tolerate MTX may also consider . All patient take folic acid 1 mg daily , 5 mg weekly post MTX dose , minimize toxicity , accord local guideline . In addition methotrexate , patient may either stable dose nonsteroidal antiinflammatory drug ( NSAIDs ) and/or stable dose oral corticosteroid ( prednisone equivalent ≤ 10 mg daily ) least 4 week prior randomization . Patients fail DMARDs allow . Negative purify protein derivative ( PPD ) tuberculin skin test reaction ( PPD 5 tuberculin unit accord local standard practice ) . RA patient : Previous treatment antiTumor Necrosis Factor ( TNF ) α anti IL1 therapy ( biological therapy ) , immunosuppressive agent cyclosporine , mycophenolate tacrolimus . The follow washout period require patient eligible participate trial . 1 . 2 month washout prior screen etanercept adalimumab 2 . 3 month washout prior screen infliximab 3 . 3 month washout prior screen rituximab 4 . 1 month washout prior screen cyclosporine , mycophenolate tacrolimus . If patient discontinue DMARDs ( disease modify antirheumatic drug ) lack efficacy toxicity , patient least 1 month agent . Patients congestive heart failure , QT prolongation syndrome poorly control diabetes mellitus . Patients history QTc prolongation exclude . Patients receive intraarticular systemic corticosteroid injection require treatment acute RA flare ( part regular therapeutic regimen ) within 4 week prior randomization . Exclusion criteria 26 Health Volunteer section also applies . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>